ReviewDiagnostics (Basel, Switzerland)2024
Enhancing Cervical Cancer Screening: Review of p16/Ki-67 Dual Staining as a Promising Triage Strategy.
Review in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 22 citations in OpenAlex.
- Research Progress on Biomarkers Associated with Cervical Cancer Caused by HPV Infection.China CDC weekly · 2026Article
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- Biology-aligned cervical cancer screening: target-centric biomarkers and next-generation diagnostic platforms.Biomarker research · 2026Review
- Integrated bioinformatics, machine learning, and experimental validation identify a four-gene diagnostic signature for cervical cancer associated with PI3K/AKT signaling.Scientific reports · 2026Article
- The Microbiome-Mitochondria-Extracellular Vesicle Axis in HPV Persistence and Cervical Carcinogenesis.Genes · 2026Review
- PAX1 methylation for triage of HR-HPV-positive women: a comparative analysis with cytology and HPV16/18 genotyping.BMC cancer · 2026Article
- Vaginal Microbiota Composition and HPV Genotype-Specific CIN2+ Risk: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Peripheral immune cell profiles and tumor marker expression in high-risk HPV-infected cervical lesions: a comparative study.Frontiers in oncology · 2026Article
- Primary HPV Infection in Postmenopausal Women: A Cohort Study to Enable Risk-Stratified Management.International journal of women's health · 2026Article
- Non-invasive host transcriptome and HPV oncogene expression map the molecular landscape of HPV-driven cervical lesions.PloS one · 2026Article
- ROMO1 as a Diagnostic Biomarker in Cervical Neoplasia: Evidence from Normal, Pre-Invasive, and Invasive Lesions.Diagnostics (Basel, Switzerland) · 2025Article
- High-Throughput Targeted Sequencing Identifies an HPV Methylation Panel for Detecting Cervical Lesion Progression.Journal of medical virology · 2025Article
- An electrochemical immunosensor for intraepithelial neoplasia in cervicovaginal lavage using a fullerene-TCNQ platform for p16 detection.Analytical and bioanalytical chemistry · 2025Article
- Predictive determinants of CIN II + lesions in women over 65 years old: the contribution of HPV, colposcopy, and double immunostaining techniques.BMC geriatrics · 2025Article
- Immunohistochemical Expression of P16 in Cervical Lesions: An Observational Study.JNMA; journal of the Nepal Medical Association · 2025Observational
- Comparative Oncologic Outcomes in High-Risk Human Papillomavirus-Positive and -Negative Cervical Intraepithelial Neoplasia.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Elevated VAMP8 expression promotes cervical cancer progression by enhancing autophagy via HIF-1 pathway.BMC medicine · 2025Article
- CervicalMethDx: A Precision DNA Methylation Test to Identify Risk of High-Grade Intraepithelial Lesions in Cervical Cancer Screening Algorithms.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Online Conference "Chronic Viral Infections and Cancer, Openings for Vaccines and Cure" VIRCAN2024, Monitoring the Progress.Vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer, primarily caused by high-risk human papillomavirus (HR-HPV) types 16 and 18, is a major global health concern. Persistent HR-HPV infection can progress from reversible precancerous lesions to invasive cervical cancer, which is driven by the oncogenic activity of human papillomavirus (HPV) genes, particularly E6 and E7. Traditional screening methods, including cytology and HPV testing, have limited sensitivity and specificity. This review explores the application of p16/Ki-67 dual-staining cytology for cervical cancer screening. This advanced immunocytochemical method allows for simultaneously detecting p16 and Ki-67 proteins within cervical epithelial cells, offering a more specific approach for triaging HPV-positive women. Dual staining and traditional methods are compared, demonstrating their high sensitivity and negative predictive value but low specificity. The increased sensitivity of dual staining results in higher detection rates of CIN2+ lesions, which is crucial for preventing cervical cancer progression. However, its low specificity may lead to increased false-positive results and unnecessary biopsies. The implications of integrating dual staining into contemporary screening strategies, particularly considering the evolving landscape of HPV vaccination and changes in HPV genotype prevalence, are also discussed. New guidelines and further research are necessary to elucidate the long-term effects of integrating dual staining into screening protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.